MTHFR T677 Homozygosis Influences the Presence of Aura in Migraineurs

It has been suggested that folate metabolism could be involved in migraine pathogenesis. We analysed the 5′, 10′ -methylenetetrahydrofolate reductase (MTHFR) genotypic distribution in a large migraine sample. We genotyped 230 migraine patients (152 migraine without aura (MO) and 78 migraine with aura (MA)) and 204 nonheadache controls. The incidence of TT homozygosis for migraine in general (12%), MO (9%) and MA (18%) did not significantly differ from that found in healthy controls (13%). Differences were significant when the frequency of TT homozygosis between MA and MO ( P = 0.03, OR = 2.34, 95% CI = 1.04-5.26) was compared. There was a tendency for a higher frequency of the MTHFR T allele in the MA group (42%) as compared to MO (29%) and controls (36%). These differences were significant only in the case of MA vs. MO ( P = 0.006, OR = 1.75, 95% CI = 1.15-2.65). These results could indicate that the MTHFR C677T polymorphism, causing mild hyperhomocystinaemia, might be a genetic risk factor for experiencing aura among migraineurs. Overall, however, there was no association between migraine and the C677T MTHFR polymorphism.

Download Full-text

Postgraduate Symposium The MTHFR C677T polymorphism, B-vitamins and blood pressure

Proceedings of The Nutrition Society ◽

10.1017/s0029665109991728 ◽

2009 ◽

Vol 69 (1) ◽

pp. 156-165 ◽

Cited By ~ 20

Author(s):

C. P. Wilson ◽

H. McNulty ◽

J. M. Scott ◽

J. J. Strain ◽

M. Ward

Keyword(s):

Blood Pressure ◽

Methylenetetrahydrofolate Reductase ◽

Mthfr C677t ◽

Mthfr Gene ◽

B Vitamins ◽

Vitamin B ◽

C677t Polymorphism ◽

Mthfr Polymorphism ◽

Mthfr C677t Polymorphism ◽

B Vitamin

High blood pressure (BP) and elevated homocysteine are reported as independent risk factors for CVD and stroke in particular. The main genetic determinant of homocysteine concentrations is homozygosity (TT genotype) for the C677T polymorphism in the methylenetetrahydrofolate reductase (MTHFR) gene, typically found in approximately 10% of Western populations. The B-vitamins folate, vitamin B12and vitamin B6are the main nutritional determinants of homocysteine, with riboflavin more recently identified as a potent modulator specifically in individuals with the TT genotype. Although observational studies have reported associations between homocysteine and BP, B-vitamin intervention studies have shown little or no BP response despite decreases in homocysteine. Such studies, however, have not considered the MTHFR C677T polymorphism, which has been shown to be associated with BP. It has been shown for the first time that riboflavin is an important determinant of BP specifically in individuals with the TT genotype. Research generally suggests that 24 h ambulatory BP monitoring provides a more accurate measure of BP than casual measurements and its use in future studies may also provide important insights into the relationship between the MTHFR polymorphism and BP. Further research is also required to investigate the association between specific B-vitamins and BP in individuals with different MTHFR genotypes in order to confirm whether any genetic predisposition to hypertension is correctable by B-vitamin intervention. The present review will investigate the evidence linking the MTHFR C677T polymorphism to BP and the potential modulating role of B-vitamins.

Download Full-text

Association between MTHFR C677T polymorphism and folate, vitamin B12, homocysteine, and DNA fragmentation in patients with ovarian cancer

Turkish Journal of Biochemistry ◽

10.1515/tjb-2016-0151 ◽

2016 ◽

Vol 41 (6) ◽

Author(s):

Anıl Çağla Özkılıç ◽

Ahmet Çetin ◽

Burcu Bayoğlu ◽

Huriye Balcı ◽

Müjgan Cengiz

Keyword(s):

Ovarian Cancer ◽

Methylenetetrahydrofolate Reductase ◽

Case Control Study ◽

Mthfr C677t ◽

Case Control ◽

Healthy Controls ◽

Mthfr C677t Polymorphism ◽

Cerrahpasa Medical Faculty ◽

Important Enzyme ◽

Control Study

AbstractObjective:Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme that regulates the metabolism of methionine and folate.Materials and methods:This case-control study was conducted in Istanbul University Cerrahpasa Medical Faculty. We studied 50 ovarian cancer patients and 54 healthy controls. TheResults:We found no correlation between theConclusion:Our findings suggest that

Download Full-text

Methylenetetrahydrofolate reductase C677T polymorphism and toxicity to 5-FU-based chemotherapy in colorectal cancer

Tropical Journal of Pharmaceutical Research ◽

10.4314/tjpr.v19i1.30 ◽

2020 ◽

Vol 19 (1) ◽

pp. 209-213

Author(s):

Yong-lian Zhang ◽

Xiong-wei Xie

Keyword(s):

Colorectal Cancer ◽

Methylenetetrahydrofolate Reductase ◽

Direct Sequencing ◽

Skin Toxicity ◽

Mthfr C677t ◽

C677t Polymorphism ◽

Mthfr Polymorphism ◽

Mthfr C677t Polymorphism ◽

C677t Mutation ◽

Hematopoietic Toxicity

Purpose: To investigate the toxicity of methylenetetrahydrofolate reductase (MTHFR) polymorphism in colorectal cancer patients treated with 5-fluorouracil (5-FU).Methods: A total of 105 patients with colorectal cancer who underwent 5-FU therapy were included in this study. MTHFR C677T polymorphisms were determined using direct sequencing. Physical examination and the results of blood and urine tests were used to evaluate the toxicities, including gastrointestinal toxicity, hematopoietic toxicity, hair-skin toxicity and hand-foot syndrome.Results: In 90.5 % of all patients, 5-FU toxicity was observed. With regard to MTHFR C677T mutation, 45.7 % heterozygote mutants and 19.0 % homozygote mutants were observed. MTHFR C677T polymorphism was statistically related to 5-FU toxicity (p = 0.000). In addition, MTHFR C677T mutation was closely related to hematopoietic toxicity (p = 0.005).Conclusion: MTHFR C677T can be used for the prediction of 5-FU toxicity, and can also predict hematopoietic toxicity in patients with colorectal cancer. Keywords: MTHFR genes, Polymorphism, Colorectal cancer, Biomarker, Toxicity

Download Full-text

Methylenetetrahydrofolate Reductase Polymorphisms and Pregnancy Outcome

Geburtshilfe und Frauenheilkunde ◽

10.1055/a-0664-8237 ◽

2018 ◽

Vol 78 (09) ◽

pp. 871-878 ◽

Cited By ~ 9

Author(s):

Mert Turgal ◽

Fatma Gumruk ◽

Ergun Karaagaoglu ◽

Mehmet Beksac

Keyword(s):

Pregnancy Outcome ◽

Pregnancy Outcomes ◽

Methylenetetrahydrofolate Reductase ◽

Mthfr C677t ◽

Study Groups ◽

Mthfr Polymorphism ◽

Mthfr C677t Polymorphism ◽

Mthfr Polymorphisms ◽

Group I ◽

Significant Difference

Abstract Introduction Aim of the study was to evaluate the effect of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on pregnancy outcome. Materials and Methods A total of 617 pregnancies of women who were investigated for MTHFR C677T and A1298C polymorphisms prior to pregnancy were included in the study. Cases were classified into “homozygous polymorphisms” (Group I), “heterozygous polymorphisms” (Group II), and patients without polymorphisms who functioned as controls (Group III). Patients with polymorphisms were assigned to a specific protocol at least 3 months before becoming pregnant. Administration of low molecular weight heparin (LMWH) was started very early during pregnancy. The Beksac Obstetrics Index (BOI) was used to estimate the obstetric risk levels for the different groups. Results We found that the early pregnancy loss (EPL) rate increased as MTHFR polymorphism complexity increased and that the early EPL rate was significantly higher in patients with MTHFR C677T polymorphism compared to patients with MTHFR A1298C polymorphism (p = 0.039). There were significant differences between the previous pregnancies of the patients in the 3 study groups in terms of perinatal complications and EPLs (p = 0.003 and p = 0.019). The BOI decreased as the severity of polymorphisms increased. An association between MTHFR polymorphisms and congenital malformations and chromosomal abnormalities was observed. We could not demonstrate any statistically significant difference between study groups when the 3 groups were compared with regard to the pregnancy outcomes under specific management protocols. Conclusion MTHFR polymorphisms are potential risk factors for adverse pregnancy outcomes.

Download Full-text

Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and high plasma homocysteine in chronic hepatitis C (CHC) infected patients from the Northeast of Brazil

Nutrition Journal ◽

10.1186/1475-2891-10-86 ◽

2011 ◽

Vol 10 (1) ◽

Cited By ~ 3

Author(s):

Erika RF Siqueira ◽

Cláudia PMS Oliveira ◽

Maria TC Muniz ◽

Filipe Silva ◽

Leila MMB Pereira ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Methylenetetrahydrofolate Reductase ◽

Mthfr C677t ◽

High Plasma ◽

Plasma Homocysteine ◽

C677t Polymorphism ◽

Mthfr C677t Polymorphism

Download Full-text

Effect of maternal serum B vitamins, homocysteine levels and the 5, 10‐methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on postnatal growth measurements in their infants

The FASEB Journal ◽

10.1096/fasebj.20.4.a602 ◽

2006 ◽

Vol 20 (4) ◽

Author(s):

Hyesook Kim ◽

Young Ju Kim ◽

Ki Nam Kim ◽

Namsoo Chang

Keyword(s):

Methylenetetrahydrofolate Reductase ◽

Mthfr C677t ◽

Postnatal Growth ◽

Maternal Serum ◽

B Vitamins ◽

C677t Polymorphism ◽

Mthfr C677t Polymorphism

Download Full-text

Effect of riboflavin supplementation on blood pressure and possible effect modification by the MTHFR C677T polymorphism: a randomised trial in rural Gambia

F1000Research ◽

10.12688/f1000research.25113.1 ◽

2020 ◽

Vol 9 ◽

pp. 1034

Author(s):

Modou Jobe ◽

Mary Ward ◽

Bakary Sonko ◽

Abdul Khalie Muhammad ◽

Ebrima Danso ◽

...

Keyword(s):

Blood Pressure ◽

Large Scale ◽

Methylenetetrahydrofolate Reductase ◽

Controlled Trial ◽

Randomised Trial ◽

Mthfr C677t ◽

C677t Polymorphism ◽

Phenotypic Effect ◽

Riboflavin Deficiency ◽

Mthfr C677t Polymorphism

Introduction: Emerging evidence links a functional polymorphism in the methylenetetrahydrofolate reductase (MTHFR) gene (rs1801133) with hypertension in adults. This variant reduces the affinity of MTHFR for its cofactor flavin-adenine dinucleotide (FAD) which is derived from riboflavin. Previous work has demonstrated a blood pressure (BP)-lowering effect of riboflavin in Irish adults with the MTHFR 677TT variant. We hypothesize that the almost-universal severe riboflavin deficiency seen in rural Gambia mimics the BP phenotypic effect of the TT variant and exacerbate the effect of the CT variant. We will test this in a randomised, placebo-controlled trial, whether intervention with riboflavin can decrease BP in adults in rural Gambia. Methods: This is a phase 2 recall-by-genotype randomised single-blind placebo-controlled riboflavin supplementation trial. We will use the Keneba biobank to recruit approximately 102 individuals aged between 18-70, previously genotyped for the MTHFR C677T polymorphism and identified as carrying the T allele; these individuals will be age- and sex-matched to a similar number of homozygotes for the C allele. The participants will be randomised to a 16-week supplementation trial of 5 mg/day riboflavin or placebo, supplied every 14 days. The primary outcome, BP, will be measured at baseline and at weeks 8 and 16. Blood samples, collected at baseline and week 16, will be analysed for riboflavin, homocysteine, red cell folate, cobalamin (vitamin B12) and pyridoxine (vitamin B6). Discussion: The study will evaluate the role of riboflavin supplementation in BP control within a population with high levels of riboflavin deficiency and will test a possible gene-nutrient interaction with the MTHFR C677T polymorphism. If improvements in BP are observed in this study, and proven in subsequent large-scale interventions, riboflavin could offer a cost-effective, safe and accessible option for the prevention and control of hypertension in this population. Trial registration: ClinicalTrials.gov Identifier NCT03151096. Registered on 12 May 2017.

Download Full-text

MTHFR Gene Polymorphism and Age of Onset of Schizophrenia and Bipolar Disorder

BioMed Research International ◽

10.1155/2014/318483 ◽

2014 ◽

Vol 2014 ◽

pp. 1-9 ◽

Cited By ~ 12

Author(s):

Mohamed A. El-Hadidy ◽

Hanaa M. Abdeen ◽

Sherin M. Abd El-Aziz ◽

Mohammad Al-Harrass

Keyword(s):

Bipolar Disorder ◽

Healthy Subjects ◽

Methylenetetrahydrofolate Reductase ◽

Age Of Onset ◽

Age At Onset ◽

Mthfr C677t ◽

Control Group ◽

C677t Polymorphism ◽

Mthfr C677t Polymorphism ◽

Mthfr Gene Polymorphism

Objective. Several studies with contradictory results from different cultures about association of methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in schizophrenia and bipolar disorders. Little is known about this association in Arab culture and Egypt. So the present study aimed to assess the association of MTHFR C677T polymorphism in bipolar disorder (BD) and schizophrenia in comparison to control group. The association between MTHFR C677T polymorphism and the age at onset in schizophrenia or BD was also studied.Methods. Polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) were used to examine the genotype and allele frequencies of MTHFR C677T polymorphism in 149 healthy subjects and 134 bipolar and 103 schizophrenia patients.Results. In BD and schizophrenia, there was a higher prevalence of MTHFR C677T polymorphism than healthy subjects. Earlier age at onset was found in patients with BD, carrying one copy of the T allele or CT genotypes but not in patients with schizophrenia.Conclusion. The present findings suggest that the MTHFR C677T polymorphisms are likely to be associated with the risk of developing BD and schizophrenia and influence the age at onset of BD but not the age at onset of schizophrenia.

Download Full-text